Rambam Health Care Campus

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

Retrieved on: 
Wednesday, January 17, 2024

REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced that the final patient has been enrolled in its Phase I clinical trial.

Key Points: 
  • The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica's microbiome-based immuno-oncology drug, BMC128
    REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced that the final patient has been enrolled in its Phase I clinical trial.
  • Bristol Myers Squibb's Opdivo® is the immune checkpoint inhibitor in the trial.
  • Biomica remains on track with preliminary results, and the first data point readout is expected in H1 2024.
  • Dr. Elran Haber, CEO of Biomica, stated: "We are pleased to complete the Phase 1 Proof of Concept study enrollment, marking a critical step forward in developing our groundbreaking BMC128.

Limaca Medical Receives FDA 510(k) Clearance for its Breakthrough Precision GI™ Endoscopic Biopsy Device

Retrieved on: 
Monday, September 11, 2023

YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration ("FDA").

Key Points: 
  • YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration ("FDA").
  • This follows Limaca's receipt of FDA Breakthrough Device Designation for its Precision GI™.
  • FDA clearance allows us to bring Precision GI™ to market to fulfill our mission to always achieve precise, efficient, and definitive biopsy samples."
  • Carl Rickenbaugh, Limaca Vice Chair, added, "We are pleased with FDA's clearance of Precision GI™, following our FDA Breakthrough Device Designation.

Preeclampsia Foundation-funded Genetic Research Study Finds Two Distinct Molecular "Faces" of Preeclampsia

Retrieved on: 
Tuesday, August 29, 2023

For this study, single-cell transcriptomic research measured tens of thousands of placental cells, one cell at a time, using single-cell RNA sequencing.

Key Points: 
  • For this study, single-cell transcriptomic research measured tens of thousands of placental cells, one cell at a time, using single-cell RNA sequencing.
  • "This is important because it means there is a real molecular basis for two forms of preeclampsia, and that treatments will need to be tailored to these distinct subtypes."
  • "For example, the role of inflammation has been well described in preeclampsia research, but not fully understood," said Zeisel.
  • "We are looking forward to the continued growth of research stemming from this important finding related to preeclampsia," said Clement Pappas.

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

Retrieved on: 
Monday, August 28, 2023

BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations.

Key Points: 
  • BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations.
  • Earlier, BeaMed’s family of laser technologies was cleared by the FDA.
  • BeaMed is on track to submit, in Q2 2024, the System for potential FDA approval via the 510(k) regulatory pathway.
  • We fully expect BeaMed to capitalize on this opportunity as it positions itself for FDA submission by the middle of 2024,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

Evogene Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 17, 2023

REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.

Key Points: 
  • REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.
  • Ofer Haviv, Evogene's President and Chief Executive Officer, stated: "The second quarter of 2023 marked a period of remarkable achievements for the Evogene group.
  • Revenues for the second quarter of 2023 were approximately $654 thousand compared to approximately $312 thousand in the same period the previous year.
  • This difference was mainly due to the U.S. Dollar and Shekel exchange rate differences between periods, a decrease in marketable securities value in the second quarter of 2022 and an increase in interest income during the second quarter of 2023.

Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

Retrieved on: 
Tuesday, August 15, 2023

The Davidoff Center for the Treatment and Research of Cancer, situated at Beilinson Hospital, Rabin Medical Center (RMC), holds a preeminent position as Israel's first and foremost comprehensive cancer center, known for its international leadership in cancer care.

Key Points: 
  • The Davidoff Center for the Treatment and Research of Cancer, situated at Beilinson Hospital, Rabin Medical Center (RMC), holds a preeminent position as Israel's first and foremost comprehensive cancer center, known for its international leadership in cancer care.
  • This new site at The Davidoff Center represents another milestone in Biomica's commitment to advancing cutting-edge clinical research in immuno-oncology.
  • Prof. Gal Markel, Director of Davidoff Cancer Center and Biomica's Scientific Advisory Board member, said: "I am excited about Biomica's significant progress in their Phase I clinical trial at The Davidoff Cancer Center.
  • Dr. Elran Haber, CEO of Biomica, expressed his pride: "The opening of this new site at The Davidoff Center, a world-renowned cancer institution, marks an important milestone for Biomica's BMC128 clinical program.

Smart private 5G Network and a Revolutionary Health App Set to Transform Patient Care: Synch communication™ and Rambam Hospital Join Forces

Retrieved on: 
Monday, February 27, 2023

The app features push-to-talk (PTT over cellular) functionality and uses voice recognition and keyword detection technologies to ensure a prompt and effective response in emergency situations.

Key Points: 
  • The app features push-to-talk (PTT over cellular) functionality and uses voice recognition and keyword detection technologies to ensure a prompt and effective response in emergency situations.
  • The smart network can detect and allocate resources based on emergency keywords used in communications among ER teams.
  • The Synch app offers smart tools for collaboration between the hospital's command center, teams, medical events, and patients.
  • Rambam and Synch are committed to developing digital healthcare solutions that incorporate smart networks, AI, and collaboration technologies to enhance public health and efficiency in hospitals.

Else Nutrition to Report Third Quarter 2022 Financial Results on November 14, 2022

Retrieved on: 
Monday, November 7, 2022

VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC ( BABY ) ( BABYF ) ( 0YL.F ) ("Else" or the "Company") the Plant-Based baby, toddler, and children nutrition company , announced today that it expects to report third-quarter 2022 financial results for the period ending September 31, 2022, on November 14, 2022.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC ( BABY ) ( BABYF ) ( 0YL.F ) ("Else" or the "Company") the Plant-Based baby, toddler, and children nutrition company , announced today that it expects to report third-quarter 2022 financial results for the period ending September 31, 2022, on November 14, 2022.
  • Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults.
  • Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan.
  • Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon.

GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics, and Deliver on Precision Medicine

Retrieved on: 
Sunday, October 16, 2022

At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.

Key Points: 
  • At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.
  • For more information about GE Healthcares new Omni PET/CT platform and Omni Legend system, visit gehealthcare.com .
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).
  • ii Omni Legend 32 cm has up to 2.2 increase in system sensitivity as compared to Discovery MI 25 cm.

Else Nutrition to Webcast Live at VirtualInvestorConferences.com September 15th

Retrieved on: 
Tuesday, September 13, 2022

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.

Key Points: 
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
  • Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults.